Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 6/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891830 | 1.00 | PIK3CD (0.42) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL16480429 | 0.81 | MAPT (0.49) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL16480374 | 0.81 | MAPT (0.49) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL9891501 | 0.79 | CNR2 (0.41) | CNR2HSD11B1NR1H2NR1H3MAPT | |
| SCHEMBL9892998 | 0.77 | PIK3CD (0.42) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL9893119 | 0.77 | PIK3CD (0.42) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL9891826 | 0.77 | CNR2 (0.38) | CNR2HSD11B1NR1H2NR1H3MAPT | |
| SCHEMBL9103248 | 0.77 | ATM (0.50) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL9110238 | 0.77 | ATM (0.50) | PIK3CDCNR2HSD11B1NR1H2NR1H3 | |
| SCHEMBL16253001 | 0.75 | CNR2 (0.44) | CNR2HSD11B1NR1H2NR1H3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PIK3CD 999/4885CNR2 1/4885HSD11B1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.